Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.64 |
| ▸ | SIK1 | P57059 | 6/20 | 0.64 |
| ▸ | SIK2 | Q9H0K1 | 6/20 | 0.64 |
| ▸ | SIK3 | Q9Y2K2 | 6/20 | 0.64 |
| ▸ | LCK | P06239 | 10/20 | 0.56 |
| ▸ | BCR | P11274 | 3/20 | 0.56 |
| ▸ | SRC | P12931 | 3/20 | 0.56 |
| ▸ | KIT | P10721 | 2/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | YES1 | P07947 | 1/20 | 0.56 |
| ▸ | LYN | P07948 | 1/20 | 0.56 |
| ▸ | HCK | P08631 | 1/20 | 0.56 |
| ▸ | FGR | P09769 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28371011 | 0.88 | LCK (0.63) | ABL1SIK1SIK2SIK3LCK | |
| SCHEMBL20785959 | 0.88 | PKMYT1 (0.66) | ABL1SIK1SIK2SIK3LCK | |
| SCHEMBL21875019 | 0.86 | ABL1 (0.64) | ABL1SIK1SIK2SIK3LCK | |
| SCHEMBL30152032 | 0.86 | ABL1 (0.64) | ABL1SIK1SIK2SIK3LCK | |
| SCHEMBL4462679 | 0.86 | LCK (0.64) | ABL1SIK1SIK2SIK3LCK | |
| SCHEMBL21875046 | 0.85 | ABL1 (0.67) | ABL1SIK1SIK2SIK3LCK | |
| SCHEMBL30152047 | 0.84 | ABL1 (0.77) | ABL1SIK1SIK2SIK3LCK | |
| SCHEMBL21495196 | 0.84 | ABL1 (0.77) | ABL1SIK1SIK2SIK3LCK | |
| SCHEMBL22964561 | 0.83 | LCK (0.60) | ABL1SIK1SIK2SIK3LCK | |
| SCHEMBL20633284 | 0.82 | LCK (0.76) | ABL1SIK1SIK2SIK3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3901151-B1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| EP-3643713-B1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-07-30 | — | — | EP | disclosed |
| US-20250101015-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-03-27 | — | — | US | disclosed |
| US-20250084076-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-03-13 | — | — | US | disclosed |
| US-12172993-B2 | Heterocyclic kinase inhibitors and uses thereof | IOMX THERAPEUTICS AG (DE) | 2024-12-24 | — | — | US | disclosed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| EP-4139305-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-01 | — | — | EP | disclosed |
| CN-115667255-A | Halogenated heteroaryl and other heterocyclic kinase inhibitors and uses thereof | 艾欧麦克斯治疗股份公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20210387982-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-12-16 | — | — | US | disclosed |
| WO-2021214117-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901151-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2021-10-27 | — | — | EP | disclosed |
| CN-112955447-A | Heterocyclic kinase inhibitors and uses thereof | 艾欧麦克斯治疗股份公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-3643713-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | iOmx Therapeutics AG (DE) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12172993-B2 | Heterocyclic kinase inhibitors and uses thereof | LCK, SRC, CILK1 | ABL1 8/4885SIK1 10/4885SIK2 25/4885 |
| US-20210387982-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | LCK, SRC, CILK1 | ABL1 8/4885SIK1 10/4885SIK2 25/4885 |
| US-20250101015-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | LCK, SRC, CILK1 | ABL1 8/4885SIK1 10/4885SIK2 25/4885 |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | ABL1, PRKDC, PRKACA | ABL1 1/4885SIK1 164/4885SIK2 154/4885 |
| US-20250084076-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | LCK, SRC, CILK1 | ABL1 8/4885SIK1 10/4885SIK2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.